In their never-ending quest to speed drug discovery, development, and commercialization, pharmaceutical and biotechnology companies are now turning to information technology's latest darling, artificial intelligence (AI). Top firms are diving deep. Smaller companies are also trying to become players.
But how can drug developers leverage AI to reverse the decline in R&D productivity that has persisted in the face of other IT technologies?
From Bio-IT World
View Full Article
No entries found